Two Birds, One Stone

Two Birds, One Stone

Author: Scott Williams

Abnormally high levels of nitric oxide (NO) have been associated in certain cases with tumor growth. In their efforts to address this, a team led by Walter Fast, University of Texas at Austin, USA, set out to develop a single drug that blocks NO production by inhibiting two different enzyme targets. One target is NO synthase, the direct source of NO, and the other is DDAH-1, which degrades an endogenous inhibitor of NO synthase.

Fast and colleagues used a click chemistry mediated activity probe to gauge a series of dual-targeted inhibitors for potency within cultured cells. The most potent of the series was characterized in detail by X-ray crystallography and calorimetry to elucidate its interactions with the DDAH-1 active site. Their study is a combination of cell-based and in vitro work that dissects the contribution of an unusual covalent reversible bond to a compound’s potency, and provides valuable information for the development of new NO-blocking drugs.

Leave a Reply

Kindly review our community guidelines before leaving a comment.

Your email address will not be published. Required fields are marked *